NGAL has been incorporated into models with SOFA and APACHE II scores to enhance risk stratification, while NephroCheck® is being tested in clinical decision pathways and adaptive trial frameworks for sepsis and postoperative AKI prevention. This evidence concerns the gene LCN2 and acute kidney injury.